(AFX) Carl Zeiss Meditec - Ratings and Ratios
Exchange: XETRA • Country: Germany • Currency: EUR • Type: Common Stock • ISIN: DE0005313704
AFX: Diagostic, Devices, Surgical, Microscopes, Lenses
Carl Zeiss Meditec AG is a global leader in medical technology, specializing in innovative solutions for ophthalmology and microsurgery. Headquartered in Jena, Germany, the company operates in over 100 countries, with a strong presence in Europe, North America, and Asia. Founded in 1846, Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG and has established itself as a pioneer in advancing eye care and surgical precision. The company’s product portfolio includes diagnostic and surgical devices, intraocular lenses, and digital solutions for data management in ophthalmology, as well as microsurgical systems for neuro, spinal, and ENT surgeries.
The Ophthalmology segment focuses on diagnosing and treating chronic eye conditions such as cataracts, glaucoma, and retinal disorders. Its offerings include slit lamps, optical coherence tomography (OCT) devices, and fundus cameras for comprehensive eye examinations. The segment also provides surgical solutions like phacoemulsification systems, vitrectomy devices, and intraocular lenses, which are critical for cataract surgery and vision correction. Additionally, Zeiss Meditec offers digital platforms for storing, analyzing, and sharing clinical data, enhancing workflow efficiency for ophthalmologists.
The Microsurgery segment delivers precision instruments and systems for invasive surgical procedures. Its solutions cater to neurosurgery, spinal surgery, ENT, and plastic reconstructive surgery. The company’s microsurgical products are designed to enhance surgical accuracy and minimize tissue trauma, supporting surgeons in complex procedures. This segment underscores Zeiss Meditec’s commitment to advancing surgical outcomes across multiple medical specialties.
With a market capitalization of 5,042.08 million EUR, Carl Zeiss Meditec AG is a significant player in the health care equipment industry. Its forward P/E ratio of 29.15 indicates investor confidence in its growth prospects. The company’s return on equity (RoE) of 7.64% reflects its ability to generate profits from shareholders’ equity. The stock, traded under the ticker AFX on XETRA, has shown stability with an average 20-day volume of 200,307 shares.
The stock is expected to trade within a range of €55 to €62 over the next three months. The SMA 20 (56.58) and SMA 50 (58.71) indicate a bullish trend, with potential resistance at €60. The ATR of 3.70 suggests moderate volatility. With a forward P/E of 29.15, the stock is fairly valued, and its RoE of 7.64% supports long-term growth prospects. Investors should monitor earnings reports and market trends for further guidance.
Additional Sources for AFX Stock
AFX Stock Overview
| Market Cap in USD | 5,730m |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| GiC Sub-Industry | Health Care Equipment |
| IPO / Inception |
AFX Stock Ratings
| Growth Rating | -44.9 |
| Fundamental | 0.42 |
| Dividend Rating | 28.1 |
| Rel. Strength | -40.8 |
| Analysts | - |
| Fair Price Momentum | 48.05 EUR |
| Fair Price DCF | 1.87 EUR |
AFX Dividends
| Dividend Yield 12m | 1.00% |
| Yield on Cost 5y | 0.72% |
| Annual Growth 5y | -3.29% |
| Payout Consistency | 94.9% |
AFX Growth Ratios
| Growth Correlation 3m | 13.5% |
| Growth Correlation 12m | -65.4% |
| Growth Correlation 5y | -57.4% |
| CAGR 5y | -6.55% |
| CAGR/Max DD 5y | -0.09 |
| Sharpe Ratio 12m | 0.34 |
| Alpha | -50.61 |
| Beta | 1.333 |
| Volatility | 56.33% |
| Current Volume | 101.9k |
| Average Volume 20d | 192k |
As of April 30, 2025, the stock is trading at EUR 59.50 with a total of 101,860 shares traded.
Over the past week, the price has changed by +0.42%, over one month by -1.82%, over three months by +4.98% and over the past year by -40.37%.
Neither. Based on ValueRay Fundamental Analyses, Carl Zeiss Meditec is currently (April 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 0.42 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AFX as of April 2025 is 48.05. This means that AFX is currently overvalued and has a potential downside of -19.24%.
Carl Zeiss Meditec has no consensus analysts rating.
According to ValueRays Forecast Model, AFX Carl Zeiss Meditec will be worth about 55.1 in April 2026. The stock is currently trading at 59.50. This means that the stock has a potential downside of -7.34%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 61.2 | 2.9% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 55.1 | -7.3% |